Immunogenicity and Safety of Concomitant and Non-Concomitant Administration of RotaTeq® (V260) and Inactivated Poliomyelitis Vaccine in Healthy Chinese Infants (V260-074)

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

400 participants

Study Classification

INTERVENTIONAL

Study Start Date

2020-08-25

Study Completion Date

2021-05-08

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study will evaluate the immunogenicity and safety of concomitant administration of RotaTeq® (V260) and inactivated poliomyelitis vaccine (IPV) in Chinese infants. Its primary objective is to demonstrate that the immunogenicity of IPV in the concomitant-use group is non-inferior to the immunogenicity of IPV in the staggered-use group. The hypothesis to be tested is: The seroconversion percentage at 1 month post dose 3 for poliovirus types 1, 2, and 3 in the concomitant-use group is non-inferior to those of the staggered-use group.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Efficacy, Safety, and Immunogenicity of V260 in Healthy Chinese Infants (V260-024)

NCT02062385

Rotavirus Gastroenteritis

COMPLETED PHASE3

A Study of V260 in Healthy Chinese Adults, Children and Infants (V260-028)(COMPLETED)

NCT00953056

Rotavirus Gastroenteritis

COMPLETED PHASE1

Developing World Study for RotaTeq™ (V260-015)(COMPLETED)

NCT00362648

Vomiting Diarrhea Fever

COMPLETED PHASE3

Fractional Inactivated Poliovirus Vaccine Booster and Rotavirus Study

NCT02847026

Poliomyelitis

COMPLETED PHASE4

RotaTeq® and Meningococcus C Vaccine in Healthy Infants (V260-016)

NCT00443846

Meningitis, Meningococcal Rotavirus Infections

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Prevention of Rotavirus Gastroenteritis in Infants and Children Caused by Serotypes G1, G2, G3, G4, and G9

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Concomitant RotaTeq and IPV

Participants will receive RotaTeq (2 mL oral dose) and IPV (0.5 mL intramuscular \[IM\] injection ) concomitantly at Visit 2 (15 to 21 days after Visit 1 \[Day 1\]), Visit 4 (30 to 42 days after Visit 2), and Visit 6 (30 to 42 days after Visit 4).

Group Type EXPERIMENTAL

RotaTeq (V260)

Intervention Type BIOLOGICAL

Live, pentavalent rotavirus vaccine administered as a 2 mL-dose oral solution

IPV

Intervention Type BIOLOGICAL

0.5 mL dose IPV (Sabin strain based), administered via IM injection

Staggered RotaTeq and IPV

Participants will receive RotaTeq (2 mL oral dose) at Visit 1 (Day 1), Visit 3 (30 to 42 days after Visit 1), and Visit 5 (30 to 42 days after Visit 3); and IPV (0.5 mL IM injection) at Visit 2 (15 to 21 days Visit 1), Visit 4 (30 to 42 days after Visit 2), and Visit 6 (30 to 42 days after Visit 4).

Group Type ACTIVE_COMPARATOR

RotaTeq (V260)

Intervention Type BIOLOGICAL

Live, pentavalent rotavirus vaccine administered as a 2 mL-dose oral solution

IPV

Intervention Type BIOLOGICAL

0.5 mL dose IPV (Sabin strain based), administered via IM injection

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

RotaTeq (V260)

Live, pentavalent rotavirus vaccine administered as a 2 mL-dose oral solution

Intervention Type BIOLOGICAL

IPV

0.5 mL dose IPV (Sabin strain based), administered via IM injection

Intervention Type BIOLOGICAL

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

RotaTeq V260

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Healthy Chinese infant 48 days to 63 days of age.
* Infant's legally acceptable representative provides written informed consent for the study.

Exclusion Criteria

* History of rotavirus disease, congenital gastrointestinal disorders, chronic diarrhea, failure to thrive, or abdominal surgery.
* History of intussusception.
* History of poliomyelitis.
* Clinical evidence of active gastrointestinal illness. Note: Infants with gastroesophageal reflux disease \[GERD\] may participate in the study if the GERD is well controlled with or without medication.
* Known or suspected impairment of immunological function, including severe combined immunodeficiency disease (SCID).
* Has a fever, with an axillary temperature ≥37.5°C (or equivalent) at the time of vaccination or within 24 hours prior to vaccination. Note: The Visit 1 may be rescheduled after complete resolution of febrile illness.
* Has acute disease.
* Has underlying diseases such as cardiovascular, renal, liver, or blood disease.
* History of known hypersensitivity to any components of rotavirus vaccine and/or IPV.
* Uncontrolled epilepsy, encephalopathy, seizure, or other progressive neurological diseases.
* Known thrombocytopenia or any coagulation disorder that would contraindicate intramuscular injections.
* Resides in a household with an immunocompromised person, including individuals with congenital immunodeficiency (including SCID), human immunodeficiency virus (HIV) infection, leukemia, lymphoma, multiple myeloma, generalized malignance, chronic renal failure, organ or bone marrow transplantation, or with those receiving immunosuppressive chemotherapy including long-term systemic corticosteroids.
* Any condition, which in the opinion of the investigator, may interfere with the evaluation of the study objectives.
* Prior administration of any rotavirus vaccines or poliovirus vaccines.
* Has received inactivated or recombinant vaccines within 14 days prior to Visit 1 or live vaccines within 28 days prior to Visit 1.
* Has received an investigational or non-registered product other than study vaccines or is planning to use such product during the study.
* Has received immunosuppressive therapies including systemic (intramuscular, oral, or intravenous) corticosteroids. Note: Participants using non-systemic corticosteroids (e.g., topical, ophthalmic, and inhaled) are considered eligible for the study.
* Has received a blood transfusion or blood products, including immunoglobulins or is planning to receive such product during the study.
* Has participated in another interventional study prior to Visit 1 or expected to anytime during the study.
* The infant's legally acceptable representative is unlikely to adhere to the study procedures, keep appointments or is planning to permanently relocate from the area prior to the completion of the study or to leave for an extended period when study visits would need to be scheduled.
* Is or has an immediate family member (e.g., spouse, parent/legal guardian, sibling, or child) who is an investigational site or Sponsor staff member directly involved with this study.

Minimum Eligible Age

48 Days

Maximum Eligible Age

63 Days

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes